➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Mallinckrodt
Johnson and Johnson
Express Scripts
Dow

Last Updated: September 23, 2020

DrugPatentWatch Database Preview

Insulin aspart - Biologic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for insulin aspart

Identify potential brand extensions & biosimilar entrants

SponsorPhase
University Hospital, Strasbourg, FrancePhase 4
Yale UniversityEarly Phase 1
Juvenile Diabetes Research FoundationN/A

See all insulin aspart clinical trials

Recent Litigation for insulin aspart

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
NOVO NORDISK INC. v. SANDOZ INC.2020-06-04
Par Pharmaceutical, Inc. v. Eagle Pharmaceuticals, Inc.2018-05-31
SANOFI-AVENTIS U.S. LLC v. MERCK SHARP & DOHME CORP.2017-08-08

See all insulin aspart litigation

Company Disclosures: US Patents for insulin aspart

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Novo Nordisk Inc NOVOLOG MIX 50/50 insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021810 001 2017-11-21   Start Trial Novo Nordisk A/S (Basgsvaerd, DK) 2013-08-20 DISCN company
Novo Nordisk Inc NOVOLOG MIX 50/50 insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021810 001 2017-11-21   Start Trial Novo Nordisk A/S (Bagsvaerd, DK) 2014-04-08 DISCN company
Novo Nordisk Inc NOVOLOG MIX 50/50 insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021810 001 2017-11-21   Start Trial Novo Nordisk A/S (Bagsvaerd, DK) 2014-12-02 DISCN company
Novo Nordisk Inc NOVOLOG MIX 50/50 insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021810 001 2017-11-21   Start Trial Novo Nordisk A/S (Bagsvaerd, DK) 2013-06-21 DISCN company
Novo Nordisk Inc NOVOLOG MIX 50/50 insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021810 001 2017-11-21   Start Trial Novo Nordisk A/S (Bagsvaerd, DK) 2013-06-21 DISCN company
Novo Nordisk Inc NOVOLOG MIX 50/50 insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021810 001 2017-11-21   Start Trial Novo Nordisk A/S (Bagsvaerd, DK) 2016-06-20 DISCN company
Novo Nordisk Inc NOVOLOG MIX 50/50 insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021810 001 2017-11-21   Start Trial Novo Nordisk A/S (Bagsvaerd, DK) 2018-01-30 DISCN company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for insulin aspart

These patents were identified by searching patent claims

Supplementary Protection Certificates for insulin aspart

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
50/1999 Austria   Start Trial PRODUCT NAME: INSULIN ASPART
17030 Norway   Start Trial PRODUCT NAME: INSULIN GLARGINE/LIXISENATIDE; REG. NO/DATE: EU/1/16/1157 20170125
2107069/02 Switzerland   Start Trial PRODUCT NAME: INSULIN DEGLUDEC + INSULIN ASPART; REGISTRATION NO/DATE: SWISSMEDIC 62648 12.09.2013
90036-0 Sweden   Start Trial PRODUCT NAME: KOMBINATION AV INSULIN DEGLUDEK OCH INSULIN ASPART; REG. NO/DATE: EU/1/12/806/001 20130121
C/GB00/027 United Kingdom   Start Trial PRODUCT NAME: INSULIN ASPART AND PROTAMINE (NOVOMIX 30); REGISTERED: CH 55414 01 20000623; CH 55415 02 20000623; CH 55416 02 20000623; UK EU/1/00/142/001-008 20000801
00019 Netherlands   Start Trial PRODUCT NAME: INSULINE GLARGINE,DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH GESCHIKT ZOUT; REGISTRATION NO/DATE: EU/1/00/134/001 - 007 20000609
2013902172094 Italy   Start Trial PRODUCT NAME: INSULINA DEGLUDEC/INSULINA ASPART(RYZODEG); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/12/806/001-004-005-007-008, 20130121
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Boehringer Ingelheim
Johnson and Johnson
AstraZeneca
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.